Quick Answer
Syndax Pharmaceuticals Inc reported Cash and Equivalents of $134.93 million for fiscal year 2025.
Syndax Pharmaceuticals Inc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $134.93M | -12.4% |
| 2024 | $154.08M | -47.8% |
| 2023 | $295.39M | +297.3% |
| 2022 | $74.36M | -66.5% |
| 2021 | $221.97M | +92.6% |
| 2020 | $115.24M | +368.3% |
| 2019 | $24.61M | -27.1% |
| 2018 | $33.77M | -4.0% |
| 2017 | $35.17M | +47.5% |
| 2016 | $23.84M | +2.9% |
| 2015 | $23.18M | +131.6% |
| 2014 | $10.01M | -0.9% |
| 2013 | $10.10M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $116.81M | -12.2% | +7.5% |
| June 30, 2025 | $108.64M | +3.1% | -29.5% |
| March 31, 2025 | $153.99M | +34.4% | -0.1% |
| December 31, 2024 | $154.08M | -47.8% | +15.8% |
| September 30, 2024 | $133.02M | +40.7% | +26.2% |
| June 30, 2024 | $105.40M | +8.3% | -8.0% |
| March 31, 2024 | $114.61M | +99.3% | -61.2% |
| December 31, 2023 | $295.39M | +297.3% | +212.4% |
- Syndax Pharmaceuticals Inc showed a decrease of -12.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, Syndax Pharmaceuticals Inc’s cash and equivalents has grown by 1235.4% (from $10.10 million to $134.93 million).
- The most recent figure is from Syndax Pharmaceuticals Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: